Alzamend Neuro (ALZN) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing patented therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD through two lead candidates: AL001 and ALZN002.

• AL001 is a novel lithium-based formulation designed to improve safety and efficacy over existing lithium treatments, targeting neuropsychiatric and neurodegenerative disorders.

• ALZN002 is an immunotherapy vaccine using autologous dendritic cells to target amyloid-beta proteins in Alzheimer's patients.

• Pipeline advancement includes ongoing and planned clinical trials for both candidates, with partnerships such as Massachusetts General Hospital for trial execution.

Financial performance and metrics

• Financial statements for fiscal years ended April 30, 2023 and 2024 include going concern opinions due to recurring losses and dependence on additional financing.

• As of March 12, 2025, 6,597,507 shares of common stock were outstanding, with up to 75,775,110 shares registered for resale.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder, except for potential proceeds from warrant exercises, which will be used for general working capital.

• Net proceeds from the sale of preferred shares are expected to be used for working capital and general corporate purposes.